908 Devices shares surge 19.38% intraday on strong preliminary 2025 revenue growth and positive EBITDA.

908 Devices Inc. (MASS) surged 19.38% intraday after reporting preliminary unaudited full-year 2025 revenue of $56 million, a 17% year-over-year increase, and achieving positive Adjusted EBITDA in Q4. The results highlighted 20% growth in Q4 revenue to $17.2 million, driven by strong performance in U.S. state/local sales, international VipIR adoption, and federal/defense contracts. CEO Kevin Knopp emphasized the company’s strategic shift to a "stronger, simpler, and more profitable" model focused on frontline chemical detection, aligning with macro trends like increased funding for opioid crisis mitigation and defense budgets. While preliminary figures remain subject to audit, the results exceeded revenue guidance and signaled improved profitability, fueling investor optimism ahead of the full Q4/FY25 report.